SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,022,365,191.094644 with 95,022,375,662.737444 in circulation. The last known price of TRON is 0.30232528 USD and is down -8.04 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,465,217,312.79 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRX is drawing attention for holding up relatively well through broader crypto volatility, with traders discussing its steady price action, stablecoin-payment use, and prospects for a rebound after a pullback. Sentiment is split between long-term holders who see resilience and bearish traders pointing to weakness and the risk of further correction.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter results, driven by growth in Dupixent and Eylea HD, have sparked a sharp share-price breakout and renewed talk of new highs. Traders are weighing that momentum against continued declines in legacy Eylea sales and whether newer products can sustain growth.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charters steep decline has centered on persistent broadband subscriber losses and competition from fiber, fixed wireless and satellite, alongside its heavy debt burden and paused buybacks. Bulls see the depressed valuation, cash generation, mobile growth and Cox integration as a recovery case, while bears view shrinking broadband as a threat to the businesss long-term prospects.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARMs steep selloff and weakening technicals dominate discussion, with traders linking the drop to broader semiconductor weakness and concerns about Intels outlook and AI/CPU demand. Some see the pullback toward support as a buying opportunity, while others warn that high valuation and negative momentum could leave room for further declines ahead of earnings.

Sony Group Corp. engages in the development, design, manufacture, and sale of electronic equipment, instruments, devices, game consoles, and software for consumers, professionals and industrial markets. It operates through the following segments: Game and Network Services, Music, Pictures, Entertainment Technology & Services, Imaging and Sensing Solutions, Financial Services, and Others. The Game and Network Services segment deals with gaming machines, software and network services. The Music segment produces and publishes music and provides image media platforms. The Pictures segment handles film production, television program creation, and media networks. The Home Entertainment and Sound segment offers LCD televisions, home audio, Blu-ray Disc players and recorders, and memory-based portable audio devices. The Imaging and Sensing Solutions segment includes the image sensors business. The Financial Services segment manages the life insurance and non-life insurance operations and banking business. The Others segment consists of various operating activities, including the disc manufacturing and recording media businesses. The company was founded by Akio Morita and Masaru Ibuka on May 7, 1946 and is headquartered in Tokyo, Japan.

Sony Group Corporation - ADR

Sony Group Corporation

Sonys plan to end physical disc releases for new PlayStation games in 2028 is driving debate: many traders warn of consumer backlash, boycotts and weaker console demand, while others argue a digital shift could reduce costs and improve margins.

Keeta (KTA) is a cryptocurrency launched in 2025. Keeta has a current supply of 1,000,000,000 with 628,961,319.40126972 in circulation. The last known price of Keeta is 0.0592303 USD and is down -0.79 over the last 24 hours. It is currently trading on 112 active market(s) with $465,039.09 traded over the last 24 hours. More information can be found at https://keeta.com/.

Keeta

Keeta is drawing attention as its token continues to face heavy selling despite a steady stream of partnership and product announcements, including the ASK Group/UAE tokenization plans and Keeta Personal. Supporters see those developments as a path to adoption, while skeptics point to scant sustained network activity and question whether the announcements will translate into token demand.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas preliminary outlook for declining DefenCath reimbursement through 2027 has fueled concerns about CorMedixs revenue and adoption prospects. Bullish traders counter that DaVitas modeling is uncertain and not definitive guidance for CMS payments or CorMedix sales, pointing to the finalized reimbursement framework as a source of support.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is drawing attention amid a broad-market selloff and bearish concerns about stretched AI and mega-cap valuations, heavy data-center spending, and rising inflation, oil prices, and bond yields. The discussion is split between traders warning of a deeper correction and investors treating the dip as a buying opportunity or sticking with long-term index investing.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on broad-market volatility amid Iran-related oil and supply concerns, inflation, and rising Treasury yields shaping expectations for Fed policy. Traders are split between warnings of a deeper selloff and views that the Dow is showing resilience relative to tech, with some seeing rotation or buying opportunities.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barricks pullback has traders focused on bearish technical analyses that suggest the correction may have further to run, alongside put-heavy options activity. Some see more downside ahead, while others are buying the dip and remain bullish on gold miners over the longer term.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Certara (CERT) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT PR Newswire NEW YORK, July 23, 2026 NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is...

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers PR Newswire NEW YORK...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is...

Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entry into its developer program.read more...

As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models

As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models PR Newswire AUSTIN, Texas, July 6, 2026 Issued on behalf of MindWalk...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT PR Newswire NEW YORK, June 11, 2026 NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is...

CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm

CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm PR Newswire LOS ANGELES, June 8, 2026 LOS ANGELES, June 8, 2026 /PRNewswire/ --The Schall Law Firm, a...

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Radnor, PA.

Certara Inc

Certara Says AI Investments Will Drive Long-Term Growth – But Traders Are Focused On One Warning

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Certara reported first-quarter (Q1) revenue of $106.9 million inline with Wall Street expectations of $106.13 million.</li><li>The company expects to resolve execution and go-to-market challenges in the second half of the year.</li><li>Certara completed the sale of its global medical writing and related regulatory services business to Veristat, LLC for $85.0 million in cash</li></ul>&nbsp;Shares of Certara Inc (CERT) declined by more than 4% in premarket trading on Monday after the company reported a first-quarter profit miss and slashed its 2026 earnings guidance. Investors focused on management’s warning that operational challenges could linger through the year.Certara reported first-quarter (Q1) revenue of $106.9 million inline with Wall Street expectations of $106.13 million. However, adjusted earnings came in at $0.09 per share, missing analysts’ estimate of $0.11 per share.“We are taking decisive steps to sharpen our execution and position Certara for long-term growth, including divesting our Medical Writing business, reorganizing around two focused growth areas, and accelerating our enterprise-wide AI program”, said Jon Resnick, Chief Executive Officer at Certara.&nbsp;<h2 class="st-heading-2">Software Growth Offset By Services Weakness</h2>The company reported software revenue at $49.7 million, up 7% from a year-ago quarter, but services revenue declined 4% to $57.2 million year over year.“Our first quarter performance reflects improvement in software, which came in above plan across key metrics,” Chief Financial Officer John Gallagher said. “Services performance was mixed, reflecting execution and go-to-market challenges that we expect to resolve during the second half of the year.”&nbsp;<h2 class="st-heading-2">CERT Cuts 2026 Earnings Guidance</h2>Certara has cut its full year adjusted earnings guidance, the company now expects it to be in the range of $0.35 to $0.41 per share, down from the prior range of $0.44 to $0.48 per share.The company now sees full-year revenue to be in the range of $395 million to $405 million, including about $18 million in revenue tied to its Regulatory and Medical Writing business prior to its divestiture. Excluding that business, Certara expects revenue growth to be 0% to 4% for the year.“Our updated 2026 guidance reflects the impact of the divestiture during the second quarter, and revenue growth expectations of 0% - 4% excluding the Regulatory and Medical Writing Business,” said John Gallagher, CFO at Certara.<h2 class="st-heading-2">Certara Completes $85M Business Sale</h2>Last week, the company completed the sale of its global medical writing and related regulatory services business to Veristat, for $85 million in cash.&nbsp;The deal also includes $15.0 million held in escrow, to be released upon meeting certain post-closing conditions, and up to $35.0 million in contingent earn-out payments tied to the unit's financial performance after closing, the company said.The company stated that net proceeds will be used for general corporate purposes, including funding ongoing operations.<h2 class="st-heading-2">CERT Stock: What Retail Thinks About It?</h2>On Stocktwits, retail sentiment surrounding the stock has remained&nbsp; ‘bullish’ amid ‘high’ message volumes in the past 24 hours.Shares of Certara have declined more than 27% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/satl-stock-soars-pre-market-extending-300-ytd-rally-analysts-further-upside/cZXabzaReWH">This Geospatial Stock Is Up Over 300% This Year – Analysts Still See A 32% Upside Potential</a>

In this photo illustration, the logo of US drug development company Certara Inc. is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Certara has cut its full-year adjusted earnings guidance; it now expects earnings in the range of $0.35 to $0.41 per share.

Why Did CERT Stock Fall Today?

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CERT Certara Inc

Fundamentals

Latest CERT News